ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0045409;negative regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;835.4451311618078;8.16763571524637;0.027961596688182013;0.7926932703116032;[NLRP12]
GO:0007250;activation of NF-kappaB-inducing kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1337.9940718610228;6.8867018697843045;0.04478145746870162;0.8003065664753022;[CHI3L1]
GO:1904058;positive regulation of sensory perception of pain;8.0;1.0;0.875;9.628524252492122;66.22319046309637;8.16763571524637;0.0022164305877977837;0.7926932703116032;[PTAFR]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[ACTN4, CHI3L1, TLR7, NLRP12]
GO:0045765;regulation of angiogenesis;6.0;0.7043150770688792;0.675277851124584;8.817594036275793;44.93985318205118;4.1639455212923995;0.0015040964427611868;0.5360646801923071;[PROK2, HGS, C5AR1, JUP, PLK2, PRL, HHEX, CHI3L1, LRG1]
GO:1901223;negative regulation of NIK/NF-kappaB signaling;8.0;1.0;0.875;9.628524252492122;239.1998693179246;6.686031174322154;0.008005804360164796;0.7169239451870815;[NLRP12]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[CHI3L1, C5AR1, JUP, PLK2, LRG1]
GO:0009437;carnitine metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.36615998802463;68.6706074773741;7.138016298065211;0.002298343432733347;0.6552794972956795;[SLC22A4, POR]
GO:0002003;angiotensin maturation;8.0;1.0;0.875;9.628524252492122;184.72117518317427;7.379178354882098;0.00618245149511628;0.7523715242355574;[MME]
GO:0071493;cellular response to UV-B;8.0;1.0;0.875;9.628524252492122;82.44278777713699;7.697632086000634;0.0027592859132088378;0.7686572628545723;[CDKN1A, MME]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, PROK2, MAP4K1, MAP2K2, C5AR1, FPR1, PKN1]
GO:0071492;cellular response to UV-A;8.0;1.0;0.875;9.628524252492122;82.44278777713699;8.67846133901236;0.0027592859132088378;0.8188169164668168;[MME]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EHMT2, MEF2C, ATF3, PKIG, EZH2, PAWR, PAX5, AES, MMP12, FLNA, NR1H2, GMNN, TLE4, WFS1, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, EGR1, BCL11A, IFNA2, PTPRK, XPO1, ARID4A, BASP1, CCNE1, TGFB1, CBX4, HMGA1, NR4A2, MXD1, MEIS2]
GO:0048489;synaptic vesicle transport;7.0;0.7671156992804218;0.7344772148974115;9.292052015870908;108.01043080855717;5.459585514144159;0.003615011916085639;0.6301228223472235;[LIN7A, DNM2]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[SPIB, AKT1, MEF2C, ATF3, JUP, MMP12, ATAD2, BLM, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CCNE1, HMGA1, INHBA, TCF4, NUP62, CREB5, CD4, RAN, EHF, NUP85, NFE2, PAX5, EPCAM, NR1H2, GTF2H1, CDH1, MAP2K2, MAFF, RFC1, CHEK1, EBF1, IFNA2, PRL, RHOG, ARID4A, TGFB1, NR4A2, NR4A1, CKAP2, DNM2, MEIS2]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[ST6GALNAC2]
GO:0071258;cellular response to gravity;5.0;1.0;0.7902410118609202;9.628524252492122;37.20981579086828;9.777073627680469;0.0012453790478602876;0.7902410118609202;[PTAFR]
GO:0050435;amyloid-beta metabolic process;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;60.01596331221528;6.943860283624253;0.0020086802811995464;0.6782296504172152;[MME, APEH]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[CDH3, AKT1, MMP12, C5AR1, TGFB1, EGR3, NR4A1, LRG1]
GO:0060231;mesenchymal to epithelial transition;5.0;0.8259837884571596;0.7032329060895001;9.34084218004034;24.20171999872632;7.004484905440688;8.100097882234571E-4;0.6484506956670166;[BASP1]
GO:0007263;nitric oxide mediated signal transduction;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;27.814661162170232;6.832634648514029;9.309316775279788E-4;0.7003406189322132;[FPR1]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, JUP, ARHGAP6, CENPK, GMNN, RUVBL1, BLM, LIN7A, CCNH, TCL1A, FBXO5, RPA1, RPA3, H1FX, HMGA1, NASP, TCF4, NUP62, NUP54, CDA, NUP205, BRD2, GTF2H1, TLE4, MCM2, RAD51, PPP2R1A, TLN1, MGST1, CD79B, CD79A, KNTC1, TGFB1, DNM2, HIST1H2BK, REPS2]
GO:0007264;small GTPase mediated signal transduction;6.0;0.7369933605727446;0.6916169928765168;8.741221057491218;26.42836680105094;4.015022244900292;8.845336528452411E-4;0.5284487369119741;[CELSR1, PLK2, DHCR24, RGL4, CDKN1A, ARHGAP6, RALGPS2, RHOG, EPS8L1]
GO:0045410;positive regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.3044735649636;7.8311634786251565;0.02792341990494083;0.7754860644832351;[PTAFR]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[NFE2, MEF2C]
GO:0007269;neurotransmitter secretion;8.0;0.7043150770688792;0.7271575385344395;8.771074020640901;61.60461712537578;6.113511981550823;0.00206185109463042;0.6876452870438905;[LIN7A]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[NCF4]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PTAFR, AKT1]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[CDKN1A, PCNA, C5AR1, TGFB1, EZH2]
GO:2000484;positive regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.069023426578259;0.02521906460756386;0.7767511986393403;[FFAR2]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, CHI3L1, HBEGF, CD19, TGFB1]
GO:0015677;copper ion import;9.0;0.8933024483968273;0.8428918493787028;9.427853557029971;21.372061049954535;7.697632086000634;7.153036497357847E-4;0.7898978880348613;[STEAP4]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[TGFB1, SORT1, G0S2, INHBA]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[MSH6, MELK, MSH2, BTK, SFN, TGFB1, TNFRSF10C, INHBA, CD24, CDKN1A, PAWR, SORT1, G0S2, MLH1]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[IGHG1, FCGR3A, IGKC, IGLV1-44, FCGR2A, FCGR2B, IGKV3-20]
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;6.063501560976162;0.008015432820232688;0.6850877518099798;[NLRP12, CCDC22]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, ACTN4, TLN1, STXBP2, FLNA, TGFB1]
GO:0006814;sodium ion transport;7.0;0.811012628672052;0.7564256795932265;9.310070521373587;34.16983994150393;4.629579150867016;0.001143633791982704;0.5876762583299873;[SGK1, SLC22A4]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PTAFR, AKT1, FFAR2, DGAT2]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, HLA-DQA1, CDKN1A, LRRC4, FCER2, PTAFR, ALOX5, CSF3R, IGHG1, IFNA14, IFNA16, IFNA10, IFNA21, TNFRSF10C, CIITA, ACSL1, EGR1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, CXCR5, CXCR1, TGFB1, CXCL2, CD4]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[C5AR1]
GO:0036101;leukotriene B4 catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1158.1233539577065;8.390779266560578;0.03876134641361404;0.8443458537639685;[CYP4F2, CYP4F3]
GO:0006032;chitin catabolic process;7.0;0.811012628672052;0.7564256795932265;9.474373572664863;407.1521334841612;7.8311634786251565;0.013627015494584295;0.7514054297404357;[CHI3L1]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[FPR2, FCGR2B]
GO:0005980;glycogen catabolic process;8.0;0.9326813400603323;0.8413406700301662;9.593432932680852;697.8253482490202;7.292166977892469;0.023355586403854624;0.747921758369865;[PYGL]
GO:0061903;positive regulation of 1-phosphatidylinositol-3-kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1772.7488086408737;9.083926447120524;0.05933230725486248;0.9126727335416687;[FPR2]
GO:0005983;starch catabolic process;8.0;1.0;0.875;9.628524252492122;666.9679342199055;9.777073627680469;0.02232281652616981;0.875;[MGAM]
GO:0002232;leukocyte chemotaxis involved in inflammatory response;7.0;1.0;0.8509193652572005;9.628524252492122;93.27947089202779;9.083926447120524;0.0031219799446826077;0.8154717862087246;[FFAR2]
GO:0072112;glomerular visceral epithelial cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;72.77032193269073;7.8311634786251565;0.002435557186049328;0.7514054297404357;[BASP1, CD24]
GO:0097755;positive regulation of blood vessel diameter;7.0;0.7508913569872202;0.7263650437508107;9.0689084645567;39.67967046252893;5.845247994956144;0.0013280428609958766;0.6498456195510879;[PTAFR]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CSF3R, C5AR1, CXCL2, CXCR1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, VPREB3, C5AR1, FPR1, FPR2, CORO1A, NUP85, IGLV1-44, IGHA1, TGFB1, IGKV3-20, IGHM, CXCL2, TREM1, FFAR2, CXCR5, IGKC, CXCR1, EPCAM, NLRP12]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PPP2R1A, G0S2, INHBA, PPP1CA, ATF3]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[AKT1, EGR3, NR4A1, LRG1]
GO:0036336;dendritic cell migration;6.0;0.8436909121759173;0.7449657686781032;9.405380701177911;29.137022145890857;6.7325511899570465;9.751899096054872E-4;0.6674232935401965;[NLRP12, CXCR1]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[PTAFR]
GO:0032494;response to peptidoglycan;5.0;0.8653626801206646;0.7229223519212526;9.461470167828956;77.33766349313319;7.379178354882098;0.002588421997736798;0.6676125360964777;[C5AR1]
GO:0038112;interleukin-8-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;9.083926447120524;0.00101047745553359;0.8154717862087246;[CXCR1]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[REPS2, AKT1, TGFB1, HBEGF]
GO:0042572;retinol metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;118.00963323224862;6.375876246018314;0.003949676222508656;0.722303232910233;[DGAT2]
GO:0006641;triglyceride metabolic process;7.0;0.8436909121759173;0.7727648213451592;9.318369324188282;85.59385656069774;5.500407508664414;0.0028647493496168257;0.6322104610454062;[SLC22A4, DGAT2, ACSL1]
GO:0043542;endothelial cell migration;7.0;0.7980440201809971;0.7499413753476991;9.143016436710422;24.971868181253015;5.71663061713405;8.357859548042604E-4;0.6432681208679463;[EGR3, NR4A1, S100P]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[, CDA, FPR1, FPR2, JUP, PYGL, PTAFR, ALOX5, FLNA, LRG1, APEH, LIN7A, CORO1A, FCGR3B, FCGR2A, ACTN4, TLN1, STXBP2, MGST1, NBEAL2, ORM1, SPTAN1, MME, RHOG, CXCR1, C5AR1, MGAM, TGFB1, CHI3L1, S100P]
GO:0045722;positive regulation of gluconeogenesis;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;550.0459846672741;7.138016298065211;0.018409544097566184;0.7612791106150483;[DGAT2]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, C5AR1, FPR1, FPR2, CORO1A, NUP85, EGR3, NR4A1, CXCL2, FFAR2, RHOG, HBEGF, CXCR5, CXCR1]
GO:0050873;brown fat cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;6.444869117505266;7.282666309192915E-4;0.6198319182472036;[LAMB3, LRG1]
GO:0051289;protein homotetramerization;7.0;1.0;0.8509193652572005;9.628524252492122;85.45061507946225;5.433268205826786;0.002859955186148837;0.6287769539759931;[CDA, CD79A]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[BTK, CXCR5, FPR2, CXCR1]
GO:0031953;negative regulation of protein autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;780.3281191277907;7.379178354882098;0.026116879897493853;0.7926125360964777;[NLRP12]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[AKT1, PROK2, FPR1, FPR2, PNOC, GPR18, FFAR2, RHOG, PTAFR, CXCR5, GNAI2, CXCR1, FLNA, SORT1, CELSR1, RGS1, LHCGR, DGKZ, C5AR1, GNB2, CXCL2]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, FPR1, FPR2, JUP, PYGL, PTAFR, ALOX5, LRG1, APEH, FCGR3B, FCGR2A, STXBP2, MGST1, NBEAL2, ORM1, SPTAN1, MME, RHOG, CXCR1, C5AR1, MGAM, CHI3L1, S100P]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[RGS1, LHCGR, FPR1, FPR2, GNAI2, FLNA]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[AP2M1, FPR2, IGLV1-44, IGHA1, IGKV3-20, DNM2, IGKC, CXCR1, FCGR2B]
GO:0097186;amelogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;26.73958370240551;7.474488534686424;8.949498024565515E-4;0.7053660038532718;[CSF3R, ITGB4]
GO:0043315;positive regulation of neutrophil degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;798.7725987099202;8.390779266560578;0.0267342000301538;0.8615337942327104;[PTAFR]
GO:0002720;positive regulation of cytokine production involved in immune response;7.0;0.7436939687323844;0.7227663496233927;9.205667401672088;248.71967902277032;6.221725566191056;0.008324423823713482;0.6690987000520388;[FFAR2]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF10C]
GO:0045980;negative regulation of nucleotide metabolic process;8.0;0.6547035408479693;0.7023517704239847;9.136047767394327;483.07628294740357;5.75172193694532;0.016168128449820685;0.6691433273378073;[CDA, GNAI2]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[PTAFR]
GO:0010107;potassium ion import;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;121.72212082045542;6.063501560976162;0.004073929841064025;0.7253287636709003;[KCNJ15]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[FGF5, MEF2C, IFNA14, IFNA16, IFNA10, IFNA21, TGFB1, INHBA, PNOC, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, CXCL2, HBEGF, CMTM2, FCGR2B]
GO:0098706;ferric iron import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;329.4898826815344;7.9853141584524145;0.011027729851708358;0.8407982897480031;[STEAP4]
GO:0036155;acylglycerol acyl-chain remodeling;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.59385656069774;7.697632086000634;0.0028647493496168257;0.7445766281117727;[DGAT2]
GO:0046835;carbohydrate phosphorylation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;67.30508528847182;6.518977089658987;0.002252640633960971;0.6565011041187423;[PFKFB4]
GO:0045987;positive regulation of smooth muscle contraction;8.0;0.7671156992804218;0.7585578496402109;9.081980546124052;66.30038010178355;6.280566066213989;0.002219014055538479;0.6961884407023742;[PTAFR, PROK2]
GO:0045199;maintenance of epithelial cell apical/basal polarity;6.0;1.0;0.8231203125901445;9.628524252492122;34.60247581110787;7.138016298065211;0.001158113725191344;0.6881587980249038;[LIN7A]
GO:0034765;regulation of ion transmembrane transport;6.0;0.45556283921517005;0.5509017321977295;6.676594601596523;33.03735142972539;3.697140432584879;0.0011057304206669666;0.512192246247148;[, AKT1, MEF2C, ACTN4, GEM, CORO1A, CD19, TGFB1, DNM2, PTAFR, FLNA, KCNJ15, TSPAN13]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[TCL1A, AKT1, CHI3L1]
GO:0016311;dephosphorylation;5.0;0.6835726970475526;0.6320273603846966;8.32924126836186;24.405590426795786;4.076630054289783;8.168331479794688E-4;0.4987200624199847;[PPP2R1A, PFKFB4, ALPL, PTPRK, DUSP2, DUSP1, PPP1CA]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, MEF2C, FPR1, FPR2, IGHA1, HLA-DQA1, FCRL3, PAWR, PAX5, MMP12, FCER2, TLR10, PTAFR, UNG, NR1H2, PKN1, IGHG1, CD180, MSH6, MSH2, BLK, IGLV1-44, TREM1, FCGR3A, CR2, UNC93B1, FCGR2A, FCGR2B, BTK, STXBP2, CD79B, CD79A, CD19, CD24, CD200, IGHM, IFNA2, FFAR2, IGHD, TLR8, TLR7, IGKC, MLH1, C5AR1, STAP1, TGFB1, IGKV3-20, CD4]
GO:0006071;glycerol metabolic process;7.0;0.7866048967936545;0.7442218136540277;9.303101852057495;71.14030572701571;6.832634648514029;0.0023810020105647298;0.7003406189322132;[DGAT2]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, PTAFR, HLA-DQA1]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, AKT1, MEF2C, FPR1, FPR2, LRRC4, PTAFR, FLNA, NCF4, AP2M1, IFNA14, IFNA16, IFNA10, BLK, CORO1A, IFNA21, TNFRSF10C, CIITA, ITGB4, HHEX, FCGR3A, ITGB6, TSPAN13, FCGR2A, FCGR2B, BTK, CD19, EGR1, CD24, IGHM, PTPRK, CD37, IGHD, GNAI2, IGKC, SORT1, CELSR1, GEM, CCNE1, INHBA, IGKV3-20, NUP62, CD4, CDA, STMN1, IGHA1, HLA-DQA1, CDK14, CDKN1A, AES, FCER2, HBEGF, ALOX5, G0S2, ZYX, CSF3R, FGF5, IGHG1, CDH3, TLE4, IGLV1-44, CR2, P2RX5, ACSL1, TLN1, PFN1, CD79B, CD79A, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, CXCR5, CXCR1, KRT19, TSC2, C5AR1, STAP1, TGFB1, NR4A2, CXCL2, BLNK, REPS2]
GO:0045751;negative regulation of Toll signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;187.41437209568753;9.777073627680469;0.006272590372058239;0.8509193652572005;[NLRP12]
GO:0045637;regulation of myeloid cell differentiation;6.0;0.620063164412167;0.633151894796228;8.465373442686442;67.16582126229967;4.39257856489138;0.002247979592334476;0.5477569846744829;[CSF3R, HOXA9, LHCGR, MEF2C, NFE2, INHBA, MEIS2, CD4, ACIN1]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, BTK, LY9, IGHA1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, IGHD, TLR8, TLR10, TLR7, IGKC, IGHG1, IFNA14, IFNA16, CD180, IFNA10, BLK, CORO1A, IFNA21, TGFB1, TREM1, CR2, UNC93B1, HIST1H2BK]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[DUSP1, NLRP12, ATF3]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[C5AR1, FPR2, TGFB1, CHI3L1, GNAI2, CD4]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[CHI3L1]
GO:0071345;cellular response to cytokine stimulus;5.0;0.6729672293956388;0.6267246265587396;8.214830917184116;61.59823360834823;3.805811787890007;0.0020616374440603005;0.48487040368196277;[TCL1A, AKT1, BTK, STXBP2, EGR1, MME, NLRP12, ZYX, TLE4, CORO1A, CHI3L1, MCM2, CD4]
GO:1903361;protein localization to basolateral plasma membrane;6.0;1.0;0.8231203125901445;9.628524252492122;65.42666064804821;7.8311634786251565;0.002189771451718415;0.7236063770733796;[LIN7A]
GO:0050718;positive regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;998.8167007681584;6.518977089658987;0.033429496098039586;0.7658097438582601;[ORM1, NLRP12, TLR8]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, AKT1, MMP12, AP2M1, ACAP1, LIN7A, ITGB6, ACTN4, EGR2, POLA2, CD24, NUP155, NASP, NUP62, NUP133, TBC1D9, CHI3L1, NUP54, NUP35, RAN, NUP85, NUP88, CCDC22, UNC93B1, STXBP2, XPO1, TMED6, RANBP1, NUPL2, TSC2, HGS, TGFB1, DNM2]
GO:0046339;diacylglycerol metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.387362195675234;85.59385656069774;6.943860283624253;0.0028647493496168257;0.7060287030842711;[DGAT2, DGKZ]
GO:0002752;cell surface pattern recognition receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;1037.7692336294238;9.083926447120524;0.03473320231790253;0.8969813732811862;[FFAR2]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, CDKN1A, PPP2R1A, TNR, TGFB1, INHBA, SIPA1]
GO:0002879;positive regulation of acute inflammatory response to non-antigenic stimulus;9.0;1.0;0.896240625180289;9.628524252492122;203.29063041209574;9.083926447120524;0.006803954450203573;0.8607930461318132;[FFAR2]
GO:0032722;positive regulation of chemokine production;6.0;0.7140352122741334;0.6801379187272112;8.734706376470026;66.68357405504983;5.8067817141283475;0.002231839212302133;0.6200793994936333;[FFAR2, EGR1, TLR7]
GO:0050711;negative regulation of interleukin-1 secretion;10.0;0.8933024483968273;0.861892236059334;9.567899630675686;756.1696569975245;7.138016298065211;0.0253083179111982;0.7802794972956796;[NLRP12]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, GPR18]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, FPR1, FPR2, SFN, ARHGAP6, DUSP1, PTAFR, PKN1, MSH6, MSH2, BLK, E2F7, SH2B1, BTK, RACGAP1, RGL4, CD24, SPTAN1, PCNA, GNAI2, CELSR1, EPS8L1, STMN1, PLK2, CDKN1A, CIT, HBEGF, FGF5, LHCGR, MAP2K2, DGKZ, NRBP1, MELK, DHCR24, CNOT3, TREM1, PPP2R1A, CHEK1, SIK1, PRL, RALGPS2, MAP4K1, RHOG, TLR8, TLR7, SGK1, CXCR5, CXCR1, MLH1, SIPA1, TSC2, TGFB1, BLNK]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1]
GO:0042789;mRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;1288.3918881325048;6.832634648514029;0.043121317018375266;0.781850206004675;[C5AR1, FLNA]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[NLRP12, FCGR2B]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[FFAR2, BTK, TLR10, TLR7, NLRP12]
GO:1904469;positive regulation of tumor necrosis factor secretion;10.0;1.0;0.9152410118609203;9.628524252492122;775.9675723657698;7.292166977892469;0.025970936321606315;0.7881627702307852;[ORM1]
GO:0006337;nucleosome disassembly;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;96.25424468242052;6.832634648514029;0.0032215429463244545;0.6725415662651573;[NFE2, HMGA1]
GO:0090181;regulation of cholesterol metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.405380701177911;31.920461027636424;5.8067817141283475;0.0010683491040451517;0.6478784521606894;[DGAT2, POR, SCD, RAN]
GO:1902603;carnitine transmembrane transport;10.0;0.9326813400603323;0.8815816818910864;9.571365838652174;151.16368837882337;8.390779266560578;0.005059312611552043;0.8443458537639685;[SLC22A4]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[ORM1, NLRP12, BANK1]
GO:0045381;regulation of interleukin-18 biosynthetic process;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;154.99429437694414;9.777073627680469;0.005187519546987567;0.8509193652572005;[NLRP12]
GO:0032959;inositol trisphosphate biosynthetic process;8.0;1.0;0.875;9.628524252492122;361.00324016623335;9.083926447120524;0.012082453566540795;0.839552420951524;[PTAFR]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CXCR1]
GO:0071400;cellular response to oleic acid;7.0;1.0;0.8509193652572005;9.628524252492122;251.49016446024845;8.67846133901236;0.008417149478030858;0.7947362817240173;[DGAT2]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[CXCR1, AP2M1, DNM2]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AKT1, MEF2C, ABCB4, EGR1, JUP, EZH2, PTAFR, CDH1, BLM, OSBPL7, TGFB1, INHBA, ALPL, DNM2, RAD51]
GO:0015711;organic anion transport;6.0;0.43219213062620165;0.5392163779032453;6.26616670414623;28.19857810171702;3.758480413184235;9.437810319917961E-4;0.5153291757075998;[ACSL1, SLC22A4, ABCB4]
GO:0019858;cytosine metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.523163736834295;228.61631376470658;9.083926447120524;0.007651582280380199;0.839552420951524;[CDA]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[FPR2, GNAI2, RGS1, FLNA]
GO:0055072;iron ion homeostasis;9.0;0.811012628672052;0.801746939516315;9.292052015870908;38.23288616879122;5.395046993006588;0.0012796202927058053;0.6721435792979885;[STEAP4]
GO:2001076;positive regulation of metanephric ureteric bud development;8.0;1.0;0.875;9.628524252492122;356.33440017944014;9.083926447120524;0.011926191693866018;0.839552420951524;[BASP1]
GO:0060421;positive regulation of heart growth;7.0;0.8653626801206646;0.7836007053175329;9.510741216835738;214.6998545401377;6.221725566191056;0.007185810914134053;0.6690987000520388;[MEF2C, BASP1]
GO:0090399;replicative senescence;4.0;1.0;0.75;9.628524252492122;26.138269705024182;7.212124270218933;8.748243641116619E-4;0.6188283705770736;[CDKN1A, MME, CHEK1]
GO:0090276;regulation of peptide hormone secretion;8.0;0.6467165523344657;0.6983582761672329;8.781226392104918;104.36557654209204;4.458953633836253;0.003493021923942925;0.6030310961969355;[FFAR2, BLK]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[AKT1, PROK2, MEF2C, CLDN7, ATF3, CDC6, CDKN1A, FCRL3, MMP12, HBEGF, PTAFR, EPCAM, FLNA, LRG1, FGF5, CDH3, MSH6, BLM, CORO1A, TCL1A, SKP2, EGR1, EGR3, CD24, PRL, RHOG, GNAI2, CCNE1, C5AR1, LTBP3, TGFB1, NR4A1, LAMC2, MEIS2, CD4]
GO:0045821;positive regulation of glycolytic process;12.0;0.8933024483968273;0.8947715367885583;9.592156608321247;4823.688028610602;6.8867018697843045;0.1614444972802151;0.8003065664753022;[PFKFB4]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[MEF2C, MSH2, C5AR1, CORO1A, WFS1, NR4A2]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[AKT1, SKP2, HBEGF, PTAFR, GNAI2]
GO:0043097;pyrimidine nucleoside salvage;9.0;0.811012628672052;0.801746939516315;9.507896264703508;2649.2611103990594;7.292166977892469;0.08866838518485125;0.769162383550154;[CDA, DCK]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, DUSP1, PCNA, ABCB4, PTAFR, TGFB1, ALPL]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[AKT1, MEF2C, FIGNL1, ALPL]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[SKP2, MARCH1, RNF24]
GO:0055089;fatty acid homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;32.348635705990986;7.138016298065211;0.0010826797251974863;0.7159578506919597;[DGAT2, POLD1]
GO:0060539;diaphragm development;6.0;1.0;0.8231203125901445;9.628524252492122;30.16709003878503;7.57984905034425;0.0010096653549797375;0.710754145523778;[BASP1]
GO:0001774;microglial cell activation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;31.19674186509269;6.8867018697843045;0.001044126874979773;0.6753065664753021;[TLR8, TLR7, FPR2]
GO:0015939;pantothenate metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;165.9330644697462;8.16763571524637;0.005553630337739711;0.7686126355688037;[VNN2, VNN3]
GO:0097119;postsynaptic density protein 95 clustering;6.0;1.0;0.8231203125901445;9.628524252492122;32.82490209968103;7.9853141584524145;0.0010986199327823658;0.7314896500084853;[LRRC4]
GO:0050746;regulation of lipoprotein metabolic process;6.0;0.7369933605727446;0.6916169928765168;9.292052015870908;70.75951198159159;7.212124270218933;0.0023682571865975056;0.6919486831672181;[DGAT2]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1, CHI3L1]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[MEF2C, CD180, ABCB4, C5AR1, MGST1, STAP1, TNFRSF10C, ALPL, CXCL2, NR1H2]
GO:0071548;response to dexamethasone;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;124.89021324540595;6.015873511986907;0.004179963043429046;0.6826520511697386;[PCNA, ABCB4, PTAFR, TGFB1]
GO:0032930;positive regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.57516735605006;7.004484905440688;0.00483880074220378;0.7332096838060964;[TGFB1, FPR2, GNAI2]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[LRG1]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[EHF, CCNH, SPIB, MEF2C, ATF3, EGR1, EGR2, PAX5, FLNA, GTF2H1, ARID4A, C5AR1, HMGA1, MAFF, CREB5, MEIS2, POU2AF1]
GO:0006003;fructose 2,6-bisphosphate metabolic process;5.0;1.0;0.7902410118609202;9.628524252492122;72.82688802824934;8.16763571524637;0.0024374504023614934;0.7079342821725234;[PFKFB4]
GO:0006000;fructose metabolic process;6.0;0.7980440201809971;0.722142322680643;9.0689084645567;34.676020684410545;7.069023426578259;0.0011605752059146955;0.6846304993685643;[PFKFB4]
GO:0045444;fat cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[STEAP4, FFAR2, EGR2, LAMB3, NR4A2, NR4A1, LRG1]
GO:0000023;maltose metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;66.17358362000121;8.67846133901236;0.002214770291402649;0.7669372290569613;[MGAM]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, POR, SFN, TNFRSF10C, DHCR24]
GO:0032760;positive regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.9095484537234;5.587418885654044;0.002875315273172136;0.6366602269110988;[ORM1, PTAFR]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[NLRP12]
GO:0035356;cellular triglyceride homeostasis;8.0;1.0;0.875;9.628524252492122;50.566380672597894;7.8311634786251565;0.001692411254323797;0.7754860644832351;[DGAT2]
GO:0090026;positive regulation of monocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;859.35541097108;6.8867018697843045;0.028761852235543582;0.7674272657460779;[FPR2]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[NLRP12, CCDC22]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[C5AR1, CXCL2]
GO:1904300;positive regulation of transcytosis;7.0;1.0;0.8509193652572005;9.628524252492122;59.34352194186286;9.777073627680469;0.001986174273691794;0.8509193652572005;[PTAFR]
GO:1904306;positive regulation of gastro-intestinal system smooth muscle contraction;9.0;0.8436909121759173;0.8180860812682478;9.360260265897443;88.99922634012424;7.9853141584524145;0.0029787240115004016;0.8046099625986299;[PTAFR]
GO:1904303;positive regulation of maternal process involved in parturition;5.0;1.0;0.7902410118609202;9.628524252492122;118.0711512965144;9.777073627680469;0.003951735176756968;0.7902410118609202;[PTAFR]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[LRRC4, HGS, PPP2R1A]
GO:0006015;5-phosphoribose 1-diphosphate biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;251.39073302494668;7.9853141584524145;0.008413821597373791;0.7592887026755414;[PYGL]
GO:0007589;body fluid secretion;5.0;0.7980440201809971;0.6892630219514189;8.999915593069748;24.01032294004463;5.514393750639154;8.036039009155507E-4;0.572247364714141;[SLC22A4, ABCB4, PRL]
GO:0007218;neuropeptide signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;5.123113277522946;9.028936615729279E-4;0.5851165638517994;[SORT1, PNOC, PROK2]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[, SKP2, WFS1, RNF24]
GO:0010867;positive regulation of triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;585.9051526913918;7.292166977892469;0.019609718180177402;0.747921758369865;[DGAT2, NR1H2]
GO:0019432;triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;411.96489591296563;6.832634648514029;0.013788094321871398;0.7244212536750128;[DGAT2, ACSL1]
GO:0010863;positive regulation of phospholipase C activity;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;83.73920694943958;6.139487467954083;0.0028026758962042993;0.6889736746265369;[C5AR1, PTAFR]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, AKT1, TGFB1]
GO:0035589;G-protein coupled purinergic nucleotide receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;82.06132384088221;7.069023426578259;0.0027465186585576445;0.7365101867784198;[PTAFR]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, CD4, ALPL]
GO:0038178;complement component C5a signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;245.7153283963706;9.083926447120524;0.008223870911987907;0.8797934328124444;[C5AR1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[PTAFR, AKT1]
GO:1904317;cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine;6.0;1.0;0.8231203125901445;9.628524252492122;456.1864936163678;9.777073627680469;0.015268151400150165;0.8231203125901445;[PTAFR]
GO:0009972;cytidine deamination;11.0;1.0;0.9324289523296623;9.628524252492122;2918.4586051188953;7.474488534686424;0.09767818307110789;0.8146746435927894;[CDA]
GO:0045345;positive regulation of MHC class I biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.9853141584524145;0.0049295844405465;0.7592887026755414;[CIITA, NLRP12]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PPP2R1A, AKT1, TSC2, SFN, PKIG, CDKN1A, LRRC4, HHEX, NUP62, DUSP2, DUSP1, PKN1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, MEF2C, ATF3, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, TLE4, WFS1, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, EGR1, BCL11A, XPO1, CCNE1, TGFB1, CBX4, NR4A2, MXD1, MEIS2]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C5AR1, IGHG1, IGKC, CD19, IGLV1-44, CR2, IGKV3-20]
GO:1990743;protein sialylation;7.0;1.0;0.8509193652572005;9.628524252492122;166.27850826019107;8.390779266560578;0.005565192030526673;0.7800242071602487;[ST6GALNAC2]
GO:0046322;negative regulation of fatty acid oxidation;8.0;0.8933024483968273;0.8216512241984136;9.577230958104572;297.48425978725203;7.57984905034425;0.00995653045662727;0.7626338329336335;[DGAT2, AKT1]
GO:0009609;response to symbiotic bacterium;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;57.42597956597373;9.083926447120524;0.0019219958560468828;0.7876727335416686;[PTAFR]
GO:0072606;interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;8.390779266560578;0.004587596526932657;0.8443458537639685;[CHI3L1]
GO:0035336;long-chain fatty-acyl-CoA metabolic process;7.0;0.8933024483968273;0.7975705894556142;9.485423408851448;93.60244388508701;6.558197802812269;0.0031327895601034775;0.6863059058804069;[DGAT2, ACSL1, TECR]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2C, ATF3, EZH2, FLNA, ATAD2, PKN1, RUVBL1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, BTK, EGR1, EGR2, EGR3, HMGA1, MXD1, AFF3, NUP62, CREB5, EHF, HOXA9, NFE2, ZNF367, BRD2, PAWR, PAX5, AES, GTF2H1, TLE4, CNOT3, MAFF, RFC1, KLF8, EBF1, BCL11A, ARID4A, C5AR1, CBX4, NR4A2, MEIS2]
GO:1903238;positive regulation of leukocyte tethering or rolling;10.0;1.0;0.9152410118609203;9.628524252492122;440.9461040801303;8.390779266560578;0.014758069277832396;0.8443458537639685;[PTAFR]
GO:0007202;activation of phospholipase C activity;9.0;1.0;0.896240625180289;9.628524252492122;83.73920694944017;6.444869117505266;0.0028026758962043192;0.7258315315665724;[C5AR1]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[LHCGR, C5AR1, FPR1, FPR2]
GO:0002430;complement receptor mediated signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.57973408832269;218.73839564357212;7.212124270218933;0.007320977250414979;0.7650689957573628;[CR2, C5AR1, FPR1, FPR2]
GO:0060732;positive regulation of inositol phosphate biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.59462270081644;800.1222801547256;7.212124270218933;0.026779372653476994;0.7438283705770736;[LHCGR, PTAFR]
GO:1902943;positive regulation of voltage-gated chloride channel activity;10.0;1.0;0.9152410118609203;9.628524252492122;1152.1971065561047;9.083926447120524;0.03856300024635883;0.8797934328124444;[PTAFR]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[PROK2, C5AR1, FPR1, FPR2, CD19, CD24, GPR18, CXCR5, CXCR1, P2RX5, CD4]
GO:0046449;creatinine metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.5544162803384;104.72312179279828;8.390779266560578;0.0035049886417142283;0.7522251544931926;[MME]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[EHMT2, SPIB, AKT1, MEF2C, ATF3, JUP, PKIG, EZH2, MMP12, PTAFR, ATAD2, PKN1, RUVBL1, MAZ, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, NR3C2, CCNE1, HMGA1, INHBA, TCF4, MXD1, CREB5, EHF, HOXA9, NFE2, CDKN1A, ZNF367, BRD2, PAWR, PAX5, AES, EPCAM, NR1H2, GTF2H1, TLE4, WFS1, MAFF, RFC1, RBBP8, KLF8, CHEK1, EBF1, PFN1, BCL11A, PRL, XPO1, ARID4A, TGFB1, CBX4, NR4A2, NR4A1, CKAP2, MEIS2]
GO:0007567;parturition;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;7.57984905034425;0.0010979889214459554;0.585754145523778;[MAFF, PTAFR]
GO:0008406;gonad development;4.0;0.8653626801206646;0.6826813400603323;9.271849308553389;49.86610466882393;5.104244793218563;0.0016689736466849693;0.5110313160968547;[NUP107, BASP1, LHCGR, BIK, INHBA, NASP, MSH2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, FIGNL1, SFN, PLK2, CDKN1A, DUSP1, UNG, FLNA, MSH2, BLM, CORO1A, WFS1, TNFRSF10C, DHCR24, ADAMTS20, TCL1A, POR, EGR3, GNAI2, C5AR1, CBX4, NR4A2, NUP62]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCL2, CXCR1]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[NCF4, DNM2, CORO1A]
GO:0016266;O-glycan processing;9.0;0.7866048967936545;0.7895430735771163;9.277126365654233;178.64096908048714;5.666199763507158;0.0059789524686895724;0.6860103445912811;[ST6GALNAC2]
